INTANGIBLE ASSETS (Details) - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Apr. 30, 2026 |
Apr. 30, 2025 |
Apr. 30, 2024 |
|
| Intangible Asset, Indefinite-Lived [Line Items] | |||
| Intangible asset | $ 0 | $ 1,549,427 | |
| Intangible asset, impairment | (1,549,427) | 0 | |
| Cytochrome P450 [Member] | |||
| Intangible Asset, Indefinite-Lived [Line Items] | |||
| Intangible asset | 0 | 1,549,427 | $ 1,549,427 |
| Intangible asset, impairment | $ (1,549,427) | $ 0 | |
| X | ||||||||||
- Definition Amount of impairment loss for finite- and indefinite-lived intangible assets and capitalized cost for software to be sold, leased, or marketed. Excludes goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after accumulated amortization, of finite- and indefinite-lived intangible assets and capitalized cost for software to be sold, leased, or marketed. Excludes goodwill. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|